Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE, published by IOS Press, serves as an essential platform for advancing the understanding of risk and safety within the medical domain. With an ISSN of 0924-6479 and E-ISSN of 1878-6847, this journal has been dedicated to fostering critical discourse since its inception in 1990, reflecting a continuous commitment to the field through 2024. Positioned within the Q4 category in Health Policy and Q3 in Medicine (miscellaneous) and Public Health, Environmental and Occupational Health, the journal provides valuable insights, empirical research, and theoretical analyses that speak to the diverse challenges faced in medical safety and risk management. Although it operates under a subscription model, the journal remains a vital resource for researchers, healthcare professionals, and students alike, facilitating the exchange of innovative ideas and best practices in health risk assessment. With Scopus ranks indicating its role as a key contributor in its categories, the INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE continues to shape the landscape of medical safety and policy discussions around the globe.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

DRUG SAFETY is a premier academic journal published by ADIS INT LTD, dedicated to the critical field of pharmacology and toxicology. Since its inception in 1990, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals by providing high-quality, peer-reviewed articles that inform and advance the understanding of drug safety and efficacy. With an impressive impact factor and its current Q1 categorization in Pharmacology across various sub-disciplines, DRUG SAFETY is ranked among the top journals in its field, reflecting its commitment to excellence in scientific research. The journal features a diverse range of studies, reviews, and case reports addressing contemporary issues in drug safety, making it an invaluable tool for academia and industry alike. Although it is not an open-access journal, the content is accessible to subscribers and institutions, ensuring that essential findings in drug safety reach the widest audience possible. As the field evolves, DRUG SAFETY remains at the forefront, driving innovation and improving regulatory practices worldwide.